CLAIM AMENDMENTS

- 1. (Currently amended) A recombinant poxvirus comprising at least
- two homologous foreign genes which are homologous in comparison to
- each other, wherein each of said genes is inserted into a different
- insertion site of the viral genome.
- 2. (Currently amended) The recombinant poxvirus according to claim
- 1, wherein the genes have a homology of at least 50% in comparison
- 3 to each other.
- 3. (Currently amended) A recombinant poxvirus comprising at least
- two homologous foreign genes, said genes having a homology of at
- least 60% in comparison to each other.
- 4. (Currently amended) The recombinant poxvirus according to claim
- 2, wherein the genes have a homology of 65-75% in comparison to
- each other.
- 5. (Previously presented) The recombinant poxvirus according to
- claim 1, wherein the genes are derived from a flavivirus.
- 6. (original) The recombinant poxvirus according to claim 5,
- wherein the flavivirus is a Dengue virus.

- 7. (Previously presented) The recombinant poxvirus according to
- claim 5, wherein the genes are at least two homologous genes
- derived from at least two different serotypes of the virus.
- 8. (Previously presented) The recombinant poxvirus according to
- claim 5, wherein the genes are at least two PrM genes.
- 9. (Previously presented) The recombinant poxvirus according to
- claim 5, wherein the genes are 4 PrM genes.
- 10. (Previously presented) The recombinant poxvirus according to
- claim 1, wherein the poxvirus is a Vaccinia virus.
- 1 11. (original) The recombinant poxvirus according to claim 10,
- wherein the Vaccinia virus is a Modified Vaccinia Ankara (MVA)
- yirus.
- 1 12. (original) The recombinant poxvirus according claim 11,
- wherein the MVA is MVA-BN deposited at the European Collection of
- Animal Cell Cultures (ECACC) under number V00083008.
- 13. (Previously presented) The recombinant poxvirus according to
- claim 1, wherein the poxvirus is replication deficient or
- replication incompetent in mammalian cells, including human cells.

- 14. (Previously presented) The recombinant poxvirus according to
- claim 1, wherein the genes are inserted into a naturally occurring
- deletion site and/or into an intergenic region of the poxviral
- genome.
- 15. (Previously presented) The recombinant poxvirus according to
- claim 1 as medicament or vaccine.
- 16. (Previously presented) A vaccine comprising the recombinant
- 2 poxvirus according to claim 1.
- 17. (Previously presented) A pharmaceutical composition comprising
- the recombinant poxvirus according to claim 1 and a
- pharmaceutically acceptable carrier, diluent, adjuvant and/or
- 4 additive.
- 18. (Currently amended) The recombinant poxvirus according to
- 2 claim 1, the vaccine according to claim 16 or the composition
- according to claim 17 for affecting, preferably inducing, effecting
- an immune response of a living animal, including a human.

19. (Canceled)

- 20. (Currently amended) A method for affecting, preferably
- inducing, effecting an immune response in a living animal,
- including a human, comprising administering a therapeutically

- effective amount of the recombinant poxvirus according to claim 1,
- to the animal or human to be treated.
- 21. (currently amended) [[A]] An isolated cell comprising the
- recombinant poxvirus according to claim 1.
- 22. (Previously presented) A method for producing a recombinant
- poxvirus according to claim 1 comprising the steps of
- infecting a cell with a poxvirus;
- transfecting the infected cell with a first vector
- 5 construct comprising a gene being heterologous to the poxviral
- genome, and a genomic poxvirus sequence capable of directing the
- integration of the heterologous gene into an insertion site of the
- 8 poxviral genome;
- identifying, isolating and, optionally, purifying the
- generated recombinant poxvirus;
- repeating the above steps by using the recombinant
- poxvirus obtained from previous steps for infecting the cell and an
- additional vector construct comprising a further gene being
- heterologous to the poxviral genome and homologous to the gene of
- the first vector construct.

- 23. (Currently amended) A kit comprising
- two or more vector constructs, each construct
- 3 comprising a gene under transcriptional control of a poxviral
- 4 expression control element, wherein the genes included in the
- different vectors are homologous genes in comparison to each other,
- and wherein each gene is flanked by a poxviral DNA sequence capable
- of directing the integration of the gene into a poxviral genome,
- s and
- means for identifying and/or selecting recombinant
- poxviruses, which have incorporated said homologous genes into
- 11 their genome.
- 24. (original) The kit according to claim 23, wherein each
- 2 homologous gene is flanked by a poxviral DNA sequence capable of
- directing the integration of said homologous gene of each vector
- 4 construct into a different insertion site of the poxviral genome.
- 25. (Previously presented) A DNA sequence derived from or
- homologous to the recombinant poxviral genome of the recombinant
- powvirus according to claim 1, wherein said DNA sequence comprises
- at least two homologous genes and at least part of the sequences of
- 5 the poxviral genome.
- 26. (currently amended) A method for detecting cells infected with
- the recombinant poxvirus according to claim 1, said method
- comprising administering [[the]] a DNA sequence derived from or

- homologous to the recombinant poxvirus according to claim 1,
- wherein said DNA sequence comprises at least two homologous genes
- and at least one part of the sequences of the poxviral genome, to
- said cells.
- 27. (currently amended) A method for identifying the recombinant
- poxvirus according to claim 1, said method comprising administering
- [[the]] a DNA sequence derived from or homologous to the
- recombinant poxvirus according to claim 1, wherein said DNA
- sequence comprises at least two homologous genes and at least one
- part of the sequences of the poxviral genome, to said virus.